CVS Health is projected to report Q2 2026 revenue of $100.09 billion and EPS of $1.87, with shares currently trading at $104.43 against a mean analyst price target of $113.50.
The central focus for this report is the Medical Benefit Ratio (MBR) within the Aetna insurance segment, which has recently shown signs of stabilization after years of elevated Medicare Advantage costs.
Following a strong Q1 performance that triggered a guidance raise, investors are looking for proof that insurance margins are sustainably rebounding through improved underwriting and operational discipline. Analysts are also monitoring the impact of the company's exit from the Individual Exchange business and continued growth in its Health Services division.